Fusion Pharma
Latest round
- Series B
Last raised
- Apr 2019
Total raised
- $151M
Investors
- 12
About Fusion Pharma
In March 2024, AstraZeneca agreed to fully acquire Fusion Pharma from Adams Street Partners, Avidity Partners, CPP Investment Board, and more for USD 800 million, or USD 21 per share in cash, including the upfront and maximum potential contingent value payments for approximately USD 2 billion. Fusion Pharma developed a product known as FPI-1434, which utilizes the Fast-Clear linker technology to deliver alpha-emitting isotopes to tumors expressing the IGF-1R biomarker. Its approach support that the potent alpha particles cause lethal double-stranded DNA breaks specifically in cancer cells, sparing healthy tissues. The company’s FPI-1434 is currently in Phase 1 clinical trials for solid tumors. In addition, the firm developed FPI-2265, which targets prostate-specific membrane antigen (PSMA) in prostate cancer and is in Phase 2 trials. Fusion Pharma also created FPI-2059, which is a small molecule radio conjugate, targets neurotensin receptor 1 (NTSR1) for treating multiple solid tumors.
Who invested in Fusion Pharma
12 investors across 3 rounds
See all investors in Fusion Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Fusion Pharma
Who invested in Fusion Pharma?
Fusion Pharma has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Fusion Pharma raised?
Fusion Pharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Fusion Pharma last raise money?
Fusion Pharma's most recent round on record is a Series B, in Apr 2019.
What does Fusion Pharma do?
In March 2024, AstraZeneca agreed to fully acquire Fusion Pharma from Adams Street Partners, Avidity Partners, CPP Investment Board, and more for USD 800 million, or USD 21 per share in cash, including the upfront and maximum potential contingent value payments for approximately USD 2 billion.
Where is Fusion Pharma headquartered?
Fusion Pharma is headquartered in Canada.
Which VCs invest in companies like Fusion Pharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Fusion Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Fusion Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.